David Portman

4.9k total citations · 2 hit papers
70 papers, 3.2k citations indexed

About

David Portman is a scholar working on Endocrinology, Diabetes and Metabolism, Psychiatry and Mental health and Genetics. According to data from OpenAlex, David Portman has authored 70 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Psychiatry and Mental health and 19 papers in Genetics. Recurrent topics in David Portman's work include Menopause: Health Impacts and Treatments (31 papers), Sexual function and dysfunction studies (21 papers) and Estrogen and related hormone effects (18 papers). David Portman is often cited by papers focused on Menopause: Health Impacts and Treatments (31 papers), Sexual function and dysfunction studies (21 papers) and Estrogen and related hormone effects (18 papers). David Portman collaborates with scholars based in United States, Israel and Canada. David Portman's co-authors include Margery Gass, James A. Simon, Gloria Bachmann, Sheryl A. Kingsberg, David F. Archer, William E. Gibbons, Freedolph D. Anderson, Fernand Labrie, William Koltun and Isabelle Côté and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Geophysical Research Atmospheres and Cancer Research.

In The Last Decade

David Portman

67 papers receiving 3.1k citations

Hit Papers

Genitourinary syndrome of menopause 2014 2026 2018 2022 2014 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Genitourinary syndrome of menopause
    2014 429 citations David Portman et al. Menopause The Journal of The North American Menopause Society profile →
  2. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society
    2014 318 citations David Portman et al. Climacteric profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Portman United States 30 2.2k 1.1k 865 702 702 70 3.2k
Lila E. Nachtigall United States 27 1.8k 0.8× 1.4k 1.4× 451 0.5× 240 0.3× 751 1.1× 67 3.1k
Elizabeth S. Ginsburg United States 40 716 0.3× 610 0.6× 390 0.5× 120 0.2× 2.8k 4.0× 193 5.6k
Patrice Lopès France 16 472 0.2× 322 0.3× 170 0.2× 157 0.2× 735 1.0× 78 1.7k
Carlotta Pozza Italy 22 937 0.4× 145 0.1× 227 0.3× 237 0.3× 433 0.6× 68 2.1k
Melanie Davies United Kingdom 32 674 0.3× 837 0.8× 77 0.1× 130 0.2× 2.1k 2.9× 105 4.1k
Riccardo Selice Italy 27 593 0.3× 664 0.6× 173 0.2× 39 0.1× 993 1.4× 59 2.0k
Jon L. Pryor United States 24 429 0.2× 432 0.4× 922 1.1× 186 0.3× 970 1.4× 55 2.5k
Cesare Battaglia Italy 31 514 0.2× 101 0.1× 445 0.5× 169 0.2× 1.5k 2.1× 120 2.5k
Alessandro Natali Italy 23 667 0.3× 141 0.1× 759 0.9× 123 0.2× 481 0.7× 68 1.9k
Ajay K. Nangia United States 26 255 0.1× 209 0.2× 157 0.2× 68 0.1× 952 1.4× 85 1.9k

Countries citing papers authored by David Portman

Since Specialization
Citations

This map shows the geographic impact of David Portman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Portman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Portman more than expected).

Fields of papers citing papers by David Portman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Portman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Portman. The network helps show where David Portman may publish in the future.

Co-authorship network of co-authors of David Portman

This figure shows the co-authorship network connecting the top 25 collaborators of David Portman. A scholar is included among the top collaborators of David Portman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Portman. David Portman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Damodaran, Senthil, Massimo Cristofanilli, Matthew P. Goetz, et al.. (2024). Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study. Cancer Research. 84(9_Supplement). PO2–14. 1 indexed citations
2.
Goldfarb, Shari, Sarah Sammons, Jane Meisel, et al.. (2023). (114) Vaginal/Vulvar Symptoms with Lasofoxifene versus Fulvestrant in ESR1-mutated, ER+/HER2- Metastatic Breast Cancer Patients. The Journal of Sexual Medicine. 20(Supplement_2). 2 indexed citations
3.
Damodaran, Senthil, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.. (2023). Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Annals of Oncology. 34(12). 1131–1140. 25 indexed citations
4.
Simon, James A., Sheryl A. Kingsberg, David Portman, et al.. (2022). Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women s Health. 31(3). 391–400. 4 indexed citations
5.
Clayton, Anita H., Sheryl A. Kingsberg, David Portman, et al.. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women s Health. 31(2). 171–182. 5 indexed citations
6.
Kingsberg, Sheryl A., Anita H. Clayton, David Portman, et al.. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology. 134(5). 899–908. 89 indexed citations
7.
Simon, James A., Sheryl A. Kingsberg, David Portman, et al.. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology. 134(5). 909–917. 35 indexed citations
8.
Labrie, Fernand, David F. Archer, William Koltun, et al.. (2018). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause The Journal of The North American Menopause Society. 25(11). 1339–1353. 68 indexed citations
9.
Mansel, Robert E., Tapas Das, Geraldine Baggs, et al.. (2017). A Randomized Controlled Multicenter Trial of an Investigational Liquid Nutritional Formula in Women with Cyclic Breast Pain Associated with Fibrocystic Breast Changes. Journal of Women s Health. 27(3). 333–340. 5 indexed citations
10.
Edelman, Alison, James Trussell, Abigail R.A. Aiken, et al.. (2017). The emerging role of obesity in short-acting hormonal contraceptive effectiveness. Contraception. 97(5). 371–377. 7 indexed citations
11.
Labrie, Fernand, David F. Archer, William Koltun, et al.. (2016). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause The Journal of The North American Menopause Society. 23(3). 243–256. 168 indexed citations
12.
Bouchard, Céline, Fernand Labrie, Leonard R. Derogatis, et al.. (2015). Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Hormone Molecular Biology and Clinical Investigation. 25(3). 181–190. 34 indexed citations
13.
Labrie, Fernand, Leonard R. Derogatis, David F. Archer, et al.. (2015). Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The Journal of Sexual Medicine. 12(12). 2401–2412. 69 indexed citations
14.
Archer, David F., Fernand Labrie, Céline Bouchard, et al.. (2015). Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause The Journal of The North American Menopause Society. 22(9). 950–963. 70 indexed citations
15.
Kaunitz, Andrew M., David Portman, Carolyn Westhoff, et al.. (2014). Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill. Obstetrics and Gynecology. 123(2). 295–303. 16 indexed citations
16.
Portman, David, et al.. (2014). Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause The Journal of The North American Menopause Society. 21(10). 1082–1090. 21 indexed citations
17.
18.
19.
Simon, James A., et al.. (2013). Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms. Menopause The Journal of The North American Menopause Society. 20(10). 1027–1035. 92 indexed citations
20.
Anderson, Freedolph D., William E. Gibbons, & David Portman. (2006). Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. American Journal of Obstetrics and Gynecology. 195(1). 92–96. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lila E. Nachtigall Breakdown of academic impact, for papers by Elizabeth S. Ginsburg Breakdown of academic impact, for papers by Patrice Lopès Breakdown of academic impact, for papers by Carlotta Pozza Breakdown of academic impact, for papers by Melanie Davies Breakdown of academic impact, for papers by Riccardo Selice Breakdown of academic impact, for papers by Jon L. Pryor Breakdown of academic impact, for papers by Cesare Battaglia Breakdown of academic impact, for papers by Alessandro Natali Breakdown of academic impact, for papers by Ajay K. Nangia
Rankless by CCL
2026